Join Cherab's free support discussion list:

For more information about communication impairments, see Cherab's partner informational site, Speechville Express

The Late Talker

Read more about The Late Talker, a new book for families of children who are late to talk.

 

 

"the 2001 U.S. Department of Education statistics showed in children born in 1983 there were a total of 7,801 cases of speech or language impairment. Among children born in 1994, this number had risen to 211,984 cases (an approximately 30-fold increase). In children born in 1983, there were a total of 2,100 cases of autism. Among children born in 1994, this number had risen to 8,325 cases (an approximately 4-fold increase)"

Thimerosal in Childhood Vaccines, Neurodevelopment Disorders, and Heart Disease in the U.S.*

by Mark R Geier, MD., PhD and David Geier Journal Of American Physicians and Surgeons AAPS Spring 2003 Volume 8 Number 1 http://www.jpands.org/vol8no1/geier.pdf

In the United States, a tragic and massive autism epidemic is currently underway.... along with other neurodevelopmental disorders such as speech disorders, attention deficit syndrome, developmental delays, etc. Our best estimates are that thimerosal has contributed to about 75% of these cases of neurodevelopmental disorders while the MMR contributed to about 15%.... Yet, in 2003, three manufactures of childhood vaccines still are being made with full doses of thimerosal. These are as follows: Diphtheria-Tetanus-acellular-Pertussis (DTaP) manufactured by Aventis-Pasteur in multi-dose vials contains 25 micrograms of mercury, Haemophilus-influenza-Type b (HibTITTER) in multi-dose vials manufactured by Wyeth contains 25 micrograms of mercury, and pediatric hepatitis B vaccine manufactured by Merck contains 12.5 micrograms of mercury. These vaccines represent approximately half of the childhood vaccines currently available for use in the United States.... Additionally, influenza vaccines contain 25 micrograms of mercury preservative.

Letter From Mercury Researchers to Sen. Hillary Clinton

Dear Senator Hillary Clinton:


We understand that you have been given a copy of our recently published paper in the Journal of American Physicians and Surgeons implicating thimerosal as having caused neurodevelpmental disorders in children.

Dr. Mark Geier has testified before the Institute of Medicine of the United States' National Academy of Sciences on four occasions regarding vaccine policy, as well as before the U.S. House of Representatives Committee on Government Reform and has been accepted as an expert witness on vaccines in Federal, State, Canadian, and English Courts. He is board certified physician licensed to practice medicine in Maryland and Virginia.

 

He has worked at the National Institutes of Health for 10 ten years and has been a professor at the Johns Hopkins University and at the Uniformed Services University of the Health Sciences. He has published over 70 scientific articles, several of which have received national and international press coverage. David Geier is currently a graduate student at the National Institutes of Health, and has been the president of MedCon, Inc for the past 4 years providing consultation in cases involving vaccines. He has recently authored over 30 scientific articles on vaccine safety, efficacy and policy. We have been told that you seek our help in determining what should be done with regard to childhood neurodevelopmental disorders and vaccines as it applies to the National Vaccine Injury Compensation Program (NVCIP), and contemplated legislation to improve the Program.

 

We hope the following will be of help to you in your work on this matter: In the United States, a tragic and massive autism epidemic is currently underway. The peer-reviewed scientific/medical literature, (including a recent publication in The Journal of the American Medical Association), indicates that the prevalence of autism was approximately 1 per 2,500 children in the mid-1980s, while by the mid-1990s the prevalence of autism reached as high as 1 per 300 children, and some now have found that the prevalence of autism in U.S. children may be as high as approximately 1 per 150 children. These statistics are even more troubling considering that autism has been reported in the scientific/medical literature to effect males at least 5 times higher than females, therefore, presently, autism may effect as many as 1 in 30 male children. It also must be kept in mind that autism is only one of the most severe manifestations of autistic spectrum disorders, which also manifests in other neurodevelopmental disorders such as speech disorders, attention deficit syndrome, developmental delays, etc. For example, the 2001 U.S. Department of Education statistics showed in children born in 1983 there were a total of 7,801 cases of speech or language impairment. Among children born in 1994, this number had risen to 211,984 cases (an approximately 30-fold increase). In children born in 1983, there were a total of 2,100 cases of autism. Among children born in 1994, this number had risen to 8,325 cases (an approximately 4-fold increase).  Eli Lilly who has just come out with a new drug (Strattera) for the treatment of autistic spectrum disorders has estimated its drug will be of use to 5 to 7% of the current U.S. childhood population! It is ironic to note that this is the same Eli Lilly Company who makes thimerosal, the mercury preservative found in childhood vaccines, that is the apparent cause of the majority of childhood autistic spectrum disorders in the first place.

In order to determine the annual number of neurodevelopmental disorders there were in the United States, we analyzed the United States Department of Education data from their 2001 Report. This data provides a breakdown on the total number of children in each age group from 6 to 22 years old in U.S. Public Schools that have various childhood disorders.

 

In order to determine the number of children with neurodevelopmental disorders in U.S. Public Schools, we analyzed the total number of children with speech or language impairments (speech disorders) and autism. We also believe that those with developmental delays may also provide useful information on children with neurodevelopmental disorders in U.S. Public Schools, but at the present time this is a new category and limited reporting among children 6 to 9 years-old has occurred. In analyzing the U.S. Department of Education data, we analyzed the prevalence of neurodevelopmental disorders within in each childhood cohort analyzed (i.e. children 6 years-old in this report that was tabulated during the 1999-2000 school year were assumed to be born in the 1994 birth cohort). The numbers of neurodevelopmental disorders in this report are as follows for the following birth years:


1989
Autism = 5,223 cases

Speech Disorders = 72,250 cases


1990
Autism = 5,864 cases

Speech Disorders = 110,737 cases


1991
Autism = 7,020 cases

Speech Disorders = 157,790 cases
Developmental Delay = 1,027 cases


1992
Autism = 7,838 cases

Speech Disorders = 191,674 cases
Developmental Delay = 3,103 cases


1993
Autism = 8,769 cases

Speech Disorders = 213,747 cases
Developmental Delay = 5,153 cases


1994
Autism = 8,325 cases

Speech Disorders = 211,984 cases
Developmental Delay = 10,021 cases

This data shows that there has been a remarkable rise in the prevalence of neurodevelopmental disorders among children born to cohorts since 1989 and even before that. This data also illustrates the fact that children diagnosed with neurodevelopmental disorders require a significant period post-vaccination to be diagnosed with neurodevelopmental disorders.

Therefore, data regarding the more current prevalence of neurodevelopmental disorders is not available, but in order to estimate more current projections of the prevalence of neurodevelopmental disorders in U.S. children, we assumed that the prevalence of neurodevelopmental disorders did not increase since the 1994 birth cohort, (this is almost certainly an underestimate). The projected data would be as follows for those that may have had their three-year statute of limitations run before the National Vaccine Injury Compensation Act:

1995
Autism = 8,325 cases

 

Speech Disorders = 211,984 cases
Developmental Delay = 10,021 cases


1996
Autism = 8,325 cases

Speech Disorders = 211,984 cases
Developmental Delay = 10,021 cases


1997
Autism = 8,325 cases

Speech Disorders = 211,984 cases
Developmental Delay = 10,021 cases


1998
Autism = 8,325 cases

Speech Disorders = 211,984 cases
Developmental Delay = 10,021 cases


1999
Autism = 8,325 cases

Speech Disorders = 211,984 cases
Developmental Delay = 10,021 cases


2000
Autism = 8,325 cases

Speech Disorders = 211,984 cases
Developmental Delay = 10,021 cases


Total Cases Excluded From the NVCIP (1989 through 2000)
Autism = 92,989 cases

Speech Disorders = 2,230,086 cases
Developmental Delay = 79,430 cases
Overall = 2,402,505 cases

Our assumptions as to the prevalence of neurodevelopmental disorders in children are fairly reasonable because the amount of mercury that children have received from thimerosal has at least stayed the same, and perhaps even increased. The amount of mercury that children receive from thimerosal contained in childhood vaccines is of importance to this issue because we have had accepted for publication three peer-reviewed scientific/medical publications showing a direct overall and dose-response relationship between the amount of mercury from thimerosal children received and the incidence of neurodevelopmental disorders and we have several more studies on the subject in various states of submission or preparation. We have concluded in our studies that a causal relationship exists between mercury from thimerosal in childhood vaccines and neurodevelopmental disorders.


We have also had a peer-reviewed paper accepted for publication which showed that the MMR live virus vaccine may have also contributed to the ongoing epidemic of autism. Our best estimates are that the thimerosal contributed to about 75% of the cases of neurodevelpmental disorders while the MMR contributed to about 15%. The remaining 10% of the cases were related to mercury in Rhogam, a shot given to Rh-negative women, and to other sources of neurotoxicity. In 1999, the American Academy of Pediatrics recommended that thimerosal be removed from all childhood vaccines. In 2001, the Institute of Medicine also recommended that all childhood vaccines be made free of thimerosal and they stated that only a few doses of childhood vaccine containing mercury preservative remained on physician's shelves. At a hearing in December of 2002, before Congressman Burton's House Committee on Government Reform, government officials testified that thimerosal had been removed from all childhood vaccines. Unfortunately, this is not the case.

A review of the 2003 Physician's Desk Reference shows that three manufactures of childhood vaccines still are being made with full doses of thimerosal. These are as follows:


Diphtheria-Tetanus-acellular-Pertussis (DTaP) manufactured by Aventis-Pasteur in multi-dose vials contains 25 micrograms of mercury, Haemophilus-influenza-Type b (HibTITTER) in multi-dose vials manufactured by Wyeth contains 25 micrograms of mercury, and pediatric hepatitis B vaccine manufactured by Merck contains 12.5 micrograms of mercury. These vaccines represent approximately half of the childhood vaccines currently available for use in the United States.


Additionally, influenza vaccines while not officially part of the childhood vaccine schedule are being recommended for most children. Influenza vaccines contain 25 micrograms of mercury preservative. Incidentally, the fact that influenza vaccine is not formally part of the childhood vaccination schedule prevents those children who have severe adverse reactions from the vaccine from being able to seek compensation under the Vaccine Compensation Program. Also, Tetanus-diphtheria (Td) vaccine that is recommended for administration to children 7 years-old and older also still contains 25 micrograms of mercury.

It is our position that all children who have autistic spectrum disorders due to immunizations should be allowed to seek compensation both from the Vaccine Compensation Program and, if they so elect, from
civil court remedies as well. We think it is totally unfair that these innocent children should be prevented from seeking either or both remedies because the public and physicians only recently have begun to become aware that these children were damage from the thimerosal in childhood vaccines.

We think that the current three year stature of limitations should be waived to allow these innocent victims to be allowed to seek both governmental and civil remedies for the debilitating disorder from which they currently suffer, from no-fault of their own. We also feel that the government should be required to conduct an effective publicity campaign aimed at physicians and parents so that the families of all victims are made aware of the remedies available to them.


It is obvious from the relatively small number of thimerosal cases currently filed before the Vaccine Compensation Program, (around 2000-3000 cases) as compared to the much larger number of children who may be eligible for such compensation, (around 25,000 cases, from the data shown above for autism alone in the past three years) that most who are eligible even under the currently restrictive statute of limitations, (three years from the discovery of the injury), are unaware of the fact that they are eligible under the program. Finally, we plead with all involved authorities to remove mercury from all vaccines immediately.

The current epidemic of autism may well be the greatest iatrogenic epidemic in history. The damage already done to our society is already in the trillions of dollars. The damage of the 9/11 terrorist attacks, and that of the AIDS epidemic pale when compared to the current epidemic of autism. All of us alive will have to bear its effects both in the lifetime care of the damaged children and the loss of what they otherwise might have contributed to our society.


We are very familiar with the National Vaccine Injury Compensation Program having served as expert witnesses and consultants in approximately 100 cases before the program. We have done a lot of work with Congressman Burton's Committee on these matters. If we can be of any further help to you in this critical matter, we would be happy to talk to or meet with you or your staff.

We appreciate your efforts on behalf of our children in this important matter and we look forward to the opportunity to be of further help to you.


Sincerely,

Mark R. Geier, MD, Ph.D.
David A. Geier

 

*Reprinted with permission April 2003

 

 

 

 


The Cherab Foundation is a world-wide nonprofit organization working to improve the communication skills and education of all children with speech and language delays and disorders. Our area of emphasis is verbal and oral apraxia, severe neurologically-based speech and language disorders that hinder children's ability to speak.

The Cherab Foundation is committed to assisting with the development of new therapeutic approaches, preventions and cures to neurologically-based speech disorders. We bring together parents and medical, research, and educational professionals. Please join us and help to give our children a smile and a voice.

Cherab Foundation
Communication Help, Education, Research, Apraxia Base
P.O. Box 8524 PSL, Florida 34952-8524
Phone: 772-335-5135

Disclaimer | Privacy Statement | E-mail Cherab
Copyright © Cherab Foundation 1998-2002 All rights reserved.

Last Update: June 18, 2006